

Supplementary material

Effects of fibrates on lipid profile: a meta-analysis of randomized controlled trials

Elena Olmastroni^{1,2}, Federica Galimberti², Sining Xie¹, Manuela Casula^{1,2}, Alberico L Catapano^{1,2}

¹Epidemiology and Preventive Pharmacology Service (SEFAP), Department of Pharmacological and Biomolecular Sciences, University of Milan, Italy

²IRCCS MultiMedica, Sesto San Giovanni, Milan, Italy

Search Strategy

Details of searching strategies:

PubMed

(Randomized controlled trial[pt] OR controlled clinical trial[pt] OR “randomized controlled trials as topic”[MeSH Terms] OR “random allocation”[MeSH Terms] OR “double-blind method”[MeSH Terms] OR “single-blind method”[MeSH Terms] OR randomized controlled trial[Publication Type] OR (randomized[Title/Abstract] AND controlled[Title/Abstract] AND trial[Title/Abstract]) OR “single blind procedure”[All Fields] OR “double blind procedure”[All Fields] OR (“random allocation”[MeSH Terms] OR (“random”[All Fields] AND “allocation”[All Fields]) OR “random allocation”[All Fields] OR “randomization”[All Fields]) AND controlled[All Fields] AND (“clinical trials as topic”[MeSH Terms] OR (“clinical”[All Fields] AND “trials”[All Fields] AND “topic”[All Fields]) OR “clinical trials as topic”[All Fields] OR “trial”[All Fields])) OR (“controlled clinical trial”[Publication Type] OR “controlled clinical trials as topic”[MeSH Terms] OR “controlled clinical trial”[All Fields] OR (“randomized controlled trial”[Publication Type] OR “randomized controlled trials as topic”[MeSH Terms] OR “randomized controlled trials”[All Fields] OR “randomised controlled trials”[All Fields] OR (randomly[All Fields] AND controlled[All Fields] AND (“clinical trials as topic”[MeSH Terms] OR (“clinical”[All Fields] AND “trials”[All Fields] AND “topic”[All Fields]) OR “clinical trials as topic”[All Fields] OR “trial”[All Fields])) OR (randomly[All Fields] AND (“controlled clinical trial”[Publication Type] OR “controlled clinical trials as topic”[MeSH Terms] OR “controlled clinical trial”[All Fields]) OR “double-dummy trial”[All Fields] OR “double-masked trial”[All Fields] AND (((“Fibric Acids”[Mesh]) OR (((((((((((Methyl-2-Phenoxypropanoic Acid Derivatives[Title/Abstract]) OR (Methyl 2 Phenoxypropanoic Acid Derivatives[Title/Abstract])) OR (Fibric Acid Derivatives[Title/Abstract])) OR (Acid Derivatives, Fibric[Title/Abstract])) OR (2-Phenoxy Isobutyric Acids[Title/Abstract])) OR (2 Phenoxy Isobutyric Acids[Title/Abstract])) OR (Isobutyric Acids, 2-Phenoxy[Title/Abstract])) OR (2-Phenoxy-2-Methylpropionic Acid Derivatives[Title/Abstract])) OR (2 Phenoxy 2 Methylpropionic Acid Derivatives[Title/Abstract])) OR (Fibrates[Title/Abstract])) OR (Fibrate[Title/Abstract] OR (“bezafibrate”[MeSH Terms] OR “bezafibrate”[All Fields] OR “gemfibrozil”[MeSH Terms] OR “gemfibrozil”[All Fields] OR “clofibrate”[MeSH Terms] OR “clofibrate”[All Fields] OR “clofibrates”[All Fields] OR “clofibrac”[All Fields] OR “fenofibrate”[MeSH Terms] OR “fenofibrate”[All Fields] OR “procetofen”[All Fields] OR “procetofene”[All Fields] OR “ciprofibrate”[Supplementary Concept] OR “ciprofibrate”[All Fields] OR “fenofibrate”[MeSH Terms] OR “fenofibrate”[All


Fields] OR “fenofibrates”[All Fields] OR “fenofibrac”[All Fields] OR “r 2 3 benzoxazol 2 yl d4 3 4 methoxyphenoxy d7 propyl amino methyl phenoxy butanoic acid”[Supplementary Concept] OR “r 2 3 benzoxazol 2 yl d4 3 4 methoxyphenoxy d7 propyl amino methyl phenoxy butanoic acid”[All Fields] OR “pemafibrate”[All Fields]))) AND (english[Lang]) NOT (meta-analysis[Filter] OR review[Filter] OR systematicreview[Filter]).

Embase

(‘gemfibrozil’:ti OR ‘fenofibrate’:ti OR ‘bezafibrate’:ti OR ‘clofibrate’:ti OR ‘ciprofibrate’:ti OR ‘pemafibrate’:ti OR ‘fenofibrac acid’:ti) AND [english]/lim NOT (‘meta-analysis’ OR ‘review’ OR ‘commentary’ OR ‘editorial’ OR ‘protocol’ OR ‘cohort study’ OR ‘design’) AND (‘controlled clinical trial’/de OR ‘randomized controlled trial’/de) AND ‘article’/it

Web of Science

TS=(fenofibrate OR gemfibrozil OR bezafibrate OR clofibrate OR ciprofibrate OR pemafibrate OR renofibrate or fenofibrac acid) AND TS=(“randomized controlled trial” OR “controlled clinical trial”).



Supplementary Figure 1 | Flow diagram of literature search and study selection.

Supplementary references

- [s1] Niort G, Bulgarelli A, Cassader M, Pagano G. Effect of short-term treatment with bezafibrate on plasma fibrinogen, fibrinopeptide A, platelet activation and blood filterability in atherosclerotic hyperfibrinogenemic patients. *Atherosclerosis*. 1988; 71(2-3):113-119.
- [s2] Jones IR, Swai A, Taylor R, Miller M, Laker MF, Alberti KGM. Lowering of Plasma Glucose Concentrations With Bezafibrate in Patients With Moderately Controlled NIDDM. *Diabetes Care*. 1990; 13(8):855-863.
- [s3] Winocour PH, Durrington PN, Bhatnagar D, et al. Double-blind Placebo-controlled Study of the Effects of Bezafibrate on Blood Lipids, Lipoproteins, and Fibrinogen in Hyperlipidaemic Type 1 Diabetes Mellitus. *Diabetic Medicine*. 1990; 7(8):736-743.
- [s4] Niort G, Gambino R, Cassader M, Pagano G. Bezafibrate Affects Lipid, Lipo- and Apolipoprotein Pattern in Non-Insulin-Dependent Diabetic Patients. *Horm Metab Res*. 1993; 25(07):372-374.
- [s5] Walzl M. Effect of Heparin-Induced Extracorporeal Low-Density Lipoprotein Precipitation and Bezafibrate on Hemorheology and Clinical Symptoms in Cerebral Multiinfarct Disease. *Pathophysiol Haemos Thromb*. 1993; 23(4):192-202.
- [s6] Stewart MW, Dyer RG, Alberti KGMM, Laker MF. The Effects of Lipid Lowering Drugs on Metabolic Control and Lipoprotein Composition in Type 2 Diabetic Patients with Mild Hyperlipidaemia. *Diabetic Medicine*. 1995; 12(3):250-257.
- [s7] Elkeles RS, Diamond JR, Poulter C, et al. Cardiovascular Outcomes in Type 2 Diabetes: A double-blind placebo-controlled study of bezafibrate: the St. Mary's, Ealing, Northwick Park Diabetes Cardiovascular Disease Prevention (SEND CAP) Study. *Diabetes Care*. 1998; 21(4):641-648.
- [s8] Ogawa S, Takeuchi K, Sugimura K, et al. Bezafibrate reduces blood glucose in type 2 diabetes mellitus. *Metabolism*. 2000; 49(3):331-334.
- [s9] León-Martínez JM, Martínez-Abundis E, González-Ortiz M, Pérez-Rubio KG. Effect of Berberine Plus Bezafibrate Administration on the Lipid Profile of Patients with Mixed Dyslipidemia: A Pilot Clinical Trial. *Journal of Medicinal Food*. 2020; 24(2):111-115.
- [s10] Illingworth D, Olsen GD, Cook SF, Sexton GJ, Wendel HA, Connor WE. Ciprofibrate in the therapy of type II hypercholesterolemia A double-blind trial. *Atherosclerosis*. 1982; 44(2):211-221.
- [s11] Kontopoulos AG, Athyros VG, Papageorgiou AA, Hatzikonstantinou HA, Mayroudi MC, Boudoulas H. Effects of simvastatin and ciprofibrate alone and in combination on lipid profile, plasma fibrinogen and low density lipoprotein particle structure and distribution in patients with familial combined hyperlipidaemia and coronary artery disease: Coronary Artery Disease. 1996; 7(11):843-850.
- [s12] Bermúdez-Pirela V, Souki A, Cano-Ponce C, et al. Ciprofibrate Treatment Decreases Non-high Density Lipoprotein Cholesterol and Triglycerides and Increases High Density Lipoprotein Cholesterol in Patients With Frederickson Type IV Dyslipidemia Phenotype. *American Journal of Therapeutics*. 2007; 14(2):213-220.
- [s13] Cole WG. Clofibrate and Fat Embolism: A Double-Blind Trial of the Effects of Clofibrate on Sequelae to Injury. *BMJ*. 1971; 4(5780):148-149.
- [s14] Dujovne CA, Azarnoff DL, Huffman DH, Pentikainen P, Hurwitz A, Shoeman DW. One-year trials with halofenate, clofibrate, and placebo. *Clin Pharma and Therapeutics*. 1976; 19(3):352-359.
- [s15] Miettinen T, Huttunen J, Ehnholm C, Kumlin T, Mattila S, Naukkarinen V. Effect of long-term antihypertensive and hypolipidemic treatment on high density lipoprotein cholesterol and apolipoproteins A-I and A-II. *Atherosclerosis*. 1980; 36(2):249-259.
- [s16] Mellies MJ, Stein EA, Khoury P, Lamkin G, Glueck CJ. Effects of fenofibrate on lipids, lipoproteins, and apolipoproteins in 33 subjects with primary hypercholesterolemia. *Atherosclerosis*. 1987; 63(1):57-64.
- [s17] Athyros VG, Papageorgiou AA, Athyrou VV, Demitriadis DS, Kontopoulos AG. Atorvastatin and Micronized Fenofibrate Alone and in Combination in Type 2 Diabetes With Combined Hyperlipidemia. *Diabetes Care*. 2002; 25(7):1198-1202.
- [s18] Playford DA, Watts GF, Best JD, Burke V. Effect of fenofibrate on brachial artery flow-mediated dilatation in type 2 diabetes mellitus. *Am J Cardiol*. 2002; 90(11):1254-1257.
- [s19] Cavallero E, Dachet C, Assadolahi F, et al. Micronized fenofibrate normalizes the enhanced lipidemic response to a fat load in patients with type 2 diabetes and optimal glucose control. *Atherosclerosis*. 2003; 166(1):151-161.
- [s20] Playford DA, Watts GF, Croft KD, Burke V. Combined effect of coenzyme Q10 and fenofibrate on forearm microcirculatory function in type 2 diabetes. *Atherosclerosis*. 2003; 168(1):169-179.
- [s21] Vakkilainen J, Steiner G, Ansquer JC, et al. Relationships between low-density lipoprotein particle size, plasma lipoproteins, and progression of coronary artery disease: the Diabetes Atherosclerosis Intervention Study (DAIS). *Circulation*. 2003; 107(13):1733-1737.
- [s22] Derosa G, Cicero AEG, Bertone G, Piccinni MN, Ciccarelli L, Roggeri DE. Comparison of fluvastatin + fenofibrate combination therapy and fluvastatin monotherapy in the treatment of combined hyperlipidemia, type 2 diabetes mellitus, and coronary heart disease: a 12-month, randomized, double-blind, controlled trial. *Clin Ther*. 2004; 26(10):1599-1607.
- [s23] Athyros VG, Mikhailidis DP, Papageorgiou AA, et al. Targeting vascular risk in patients with metabolic syndrome but without diabetes. *Metabolism*. 2005; 54(8):1065-1074.
- [s24] Okopien B, Krysiak R, Haberka M, Herman ZS. Effect of monthly atorvastatin and fenofibrate treatment on monocyte chemoattractant protein-1 release in patients with primary mixed dyslipidemia. *J Cardiovasc Pharmacol*. 2005; 45(4):314-320.
- [s25] Keech A, Simes RJ, Barter P, et al. Effects of long-term fenofibrate therapy on cardiovascular events in 9795 people with type 2 diabetes mellitus (the FIELD study): randomised controlled trial. *Lancet*. 2005; 366(9500):1849-1861.
- [s26] Davidson MH, Rooney MW, Drucker J, Eugene Griffin H, Oosman S, Beckert M. Efficacy and tolerability of atorvastatin/fenofibrate fixed-dose combination tablet compared with atorvastatin and fenofibrate monotherapies in patients with dyslipidemia: A 12-week, multicenter, double-blind, randomized, parallel-group study. *Clinical Therapeutics*. 2009; 31(12):2824-2838.
- [s27] Derosa G, Maffioli P, Salvadeo SAT, et al. Fenofibrate, simvastatin and their combination in the management of dyslipidaemia in type 2 diabetic patients. *Curr Med Res Opin*. 2009; 25(8):1973-1983.

- [s28] Farnier M, Ducobu J, Bryniarski L. Efficacy and safety of adding fenofibrate 160 mg in high-risk patients with mixed hyperlipidemia not controlled by pravastatin 40 mg monotherapy. *Am J Cardiol.* 2010; 106(6):787-792.
- [s29] Miyazaki T, Shimada K, Miyauchi K, et al. Effects of fenofibrate on lipid profiles, cholesterol ester transfer activity, and in-stent intimal hyperplasia in patients after elective coronary stenting. *Lipids Health Dis.* 2010; 9:122.
- [s30] Krysiak R, Gdula-Dymek A, Okopien B. Effect of simvastatin and fenofibrate on cytokine release and systemic inflammation in type 2 diabetes mellitus with mixed dyslipidemia. *Am J Cardiol.* 2011; 107(7):1010-1018.e1.
- [s31] Lella M, Indira K. A comparative study of efficacy of atorvastatin alone and its combination with fenofibrate on lipid profile in type 2 diabetes mellitus patients with hyperlipidemia. *J Adv Pharm Technol Res.* 2013; 4(3):166-170.
- [s32] La Fontaine MF, Cirmigliaro CM, Hobson JC, et al. A Four Month Randomized Controlled Trial on the Efficacy of Once-daily Fenofibrate Monotherapy in Persons with Spinal Cord Injury. *Sci Rep.* 2019; 9(1):17166.
- [s33] Ihm SH, Chung WB, Lee JM, et al. Efficacy and Tolerability of Pitavastatin Versus Pitavastatin/Fenofibrate in High-risk Korean Patients with Mixed Dyslipidemia: A Multicenter, Randomized, Double-blinded, Parallel, Therapeutic Confirmatory Clinical Trial. *Clinical Therapeutics.* 2020; 42(10):2021-2035. e3.
- [s34] Park MS, Youn JC, Kim EJ, et al. Efficacy and Safety of Fenofibrate-Statin Combination Therapy in Patients With Inadequately Controlled Triglyceride Levels Despite Previous Statin Monotherapy: A Multicenter, Randomized, Double-blind, Phase IV Study. *Clin Ther.* 2021; 43(10):1735-1747.
- [s35] Frick MH, Elo O, Haapa K, et al. Helsinki Heart Study: Primary-Prevention Trial with Gemfibrozil in Middle-Aged Men with Dyslipidemia. *New England Journal of Medicine.* 1987; 317(20):1237-1245.
- [s36] Andersen P, Smith P, Seljeflot I, Brataker S, Arnesen H. Effects of Gemfibrozil on Lipids and Haemostasis after Myocardial Infarction. *Thromb Haemost.* 1990; 63(02):174-177.
- [s37] Tsai MY, Yuan J, Hunninghake DB. Effect of gemfibrozil on composition of lipoproteins and distribution of LDL subspecies. *Atherosclerosis.* 1992; 95(1):35-42.
- [s38] Lahdenperä S, Tilly-Kiesi M, Vuorinen-Markkola H, Kuusi T, Taskinen MR. Effects of Gemfibrozil on Low-Density Lipoprotein Particle Size, Density Distribution, and Composition in Patients With Type II Diabetes. *Diabetes Care.* 1993; 16(4):584-592.
- [s39] Wiklund O, Angelin B, Bergman M, et al. Pravastatin and gemfibrozil alone and in combination for the treatment of hypercholesterolemia. *Am J Med.* 1993; 94(1):13-20.
- [s40] Vinik AI, Colwell JA. Effects of Gemfibrozil on Triglyceride Levels in Patients With NIDDM: Hyperlipidemia in Diabetes Investigators. *Diabetes Care.* 1993; 16(1):37-44.
- [s41] Vuorinen-Markkola H, Yki-Järvinen H, Taskinen MR. Lowering of triglycerides by gemfibrozil affects neither the glucoregulatory nor antilipolytic effect of insulin in Type 2 (non-insulin-dependent) diabetic patients. *Diabetologia.* 1993; 36(2):161-169.
- [s42] Knipscheer HC, Nurmohamed MT, Ende A, et al. Gemfibrozil treatment of the high triglyceride-low high-density lipoprotein cholesterol trait in men with established atherosclerosis. *Journal of Internal Medicine.* 1994; 236(4):377-384.
- [s43] Avellone G, Di Garbo V, Cordova R, et al. Improvement of fibrinolysis and plasma lipoprotein levels induced by gemfibrozil in hypertriglyceridemia. *Blood Coagul Fibrinolysis.* 1995; 6(6):543-548.
- [s44] Kahri J, Sane T, van Tol A, Taskinen MR. Effect of gemfibrozil on the regulation of HDL subfractions in hypertriglyceridaemic patients. *J Intern Med.* 1995; 238(5):429-436.
- [s45] Smit JW, Jansen GH, de Bruin TW, Erkelens DW. Treatment of combined hyperlipidemia with fluvastatin and gemfibrozil, alone or in combination, does not induce muscle damage. *Am J Cardiol.* 1995; 76(2):126A-128A.
- [s46] Vanhanen HT, Miettinen TA. Cholesterol absorption and synthesis during pravastatin, gemfibrozil and their combination. *Atherosclerosis.* 1995; 115(2):135-146.
- [s47] Sane T, Knudsen P, Vuorinen-Markkola H, Yki-Järvinen H, Taskinen MR. Decreasing triglyceride by gemfibrozil therapy does not affect the glucoregulatory or antilipolytic effect of insulin in nondiabetic subjects with mild hypertriglyceridemia. *Metabolism.* 1995; 44(5):589-596.
- [s48] Schaefer EJ, Lamon-Fava S, Cole T, et al. Effects of regular and extended-release gemfibrozil on plasma lipoproteins and apolipoproteins in hypercholesterolemic patients with decreased HDL cholesterol levels. *Atherosclerosis.* 1996; 127(1):113-122.
- [s49] Frick MH, Syväne M, Nieminen MS, et al. Prevention of the Angiographic Progression of Coronary and Vein-Graft Atherosclerosis by Gemfibrozil After Coronary Bypass Surgery in Men With Low Levels of HDL Cholesterol. *Circulation.* 1997; 96(7):2137-2143.
- [s50] Yoshida H, Ishikawa T, Ayaori M, et al. Beneficial effect of gemfibrozil on the chemical composition and oxidative susceptibility of low density lipoprotein: a randomized, double-blind, placebo-controlled study. *Atherosclerosis.* 1998; 139(1):179-187.
- [s51] Rubins HB, Robins SJ, Collins D, et al. Gemfibrozil for the Secondary Prevention of Coronary Heart Disease in Men with Low Levels of High-Density Lipoprotein Cholesterol. *New England Journal of Medicine.* 1999; 341(6):410-418.
- [s52] Avogaro A, Piliago T, Catapano A, Miola M, Tiengo A. The effect of gemfibrozil on lipid profile and glucose metabolism in hypertriglyceridaemic well-controlled non-insulin-dependent diabetic patients. *Acta Diabetologica.* 1999; 36(1-2):27-33.
- [s53] Mussoni L, Mannucci L, Sirtori C, et al. Effects of gemfibrozil on insulin sensitivity and on haemostatic variables in hypertriglyceridemic patients. *Atherosclerosis.* 2000; 148(2):397-406.
- [s54] Dumont M, MaurieÁge P, Bergeron J, DespreÁs J, Prud'homme D. Effect of a six month gemfibrozil treatment and dietary recommendations on the metabolic risk profile of visceral obese men. *International Journal of Obesity.* Published online 2001.
- [s55] Bossé Y, Pascot A, Dumont M, et al. Influences of the PPAR alpha-L162V polymorphism on plasma HDL(2)-cholesterol response of abdominally obese men treated with gemfibrozil. *Genet Med.* 2002; 4(4):311-315.
- [s56] Miller J, Brown D, Amin J, et al. A randomized, double-blind study of gemfibrozil for the treatment of protease inhibitor-associated hypertriglyceridaemia. *AIDS.* 2002; 16(16):2195-2200.
- [s57] Martínez E, Domingo P, Ribera E, et al. Effects of metformin or gemfibrozil on the lipodystrophy of HIV-infected patients receiving protease inhibitors. *Antivir Ther.* 2003; 8(5):403-410.
- [s58] Ishibashi S, Yamashita S, Arai H, et al. Effects of K-877, a novel selective PPARα modulator (SPPARMα), in dyslipidaemic patients: A randomized, double blind, active- and placebo-controlled, phase 2 trial. *Atherosclerosis.* 2016; 249:36-43.
- [s59] Arai H, Yamashita S, Yokote K, et al. Efficacy and safety of K-877, a novel selective peroxisome proliferator-activated re-

- ceptor α modulator (SPPARM α), in combination with statin treatment: Two randomised, double-blind, placebo-controlled clinical trials in patients with dyslipidaemia. *Atherosclerosis*. 2017; 261:144-152.
- [s60] Arai H, Yamashita S, Yokote K, et al. Efficacy and Safety of Pemafibrate Versus Fenofibrate in Patients with High Triglyceride and Low HDL Cholesterol Levels: A Multicenter, Placebo-Controlled, Double-Blind, Randomized Trial. *J Atheroscler Thromb*. 2018; 25(6):521-538.
- [s61] Matsuba I, Matsuba R, Ishibashi S, et al. Effects of a novel selective peroxisome proliferator-activated receptor- α modulator, pemafibrate, on hepatic and peripheral glucose uptake in patients with hypertriglyceridemia and insulin resistance. *J Diabetes Investig*. 2018; 9(6):1323-1332.
- [s62] Nakajima A, Eguchi Y, Yoneda M, et al. Randomised clinical trial: Pemafibrate, a novel selective peroxisome proliferator-activated receptor α modulator (SPPARM α), versus placebo in patients with non-alcoholic fatty liver disease. *Aliment Pharmacol Ther*. 2021; 54(10):1263-1277.
- [s63] Das Pradhan A, Glynn RJ, Fruchart JC, et al. Triglyceride Lowering with Pemafibrate to Reduce Cardiovascular Risk. *N Engl J Med*. 2022; 387(21):1923-1934.